Selecting The Right CDMO Partner For Small Molecule Development

This segment of the Outsourced Pharma Live event, Small Molecule Outsourcing: Getting Timelines, Tech Transfer and Analytics Right, explores how small and emerging biopharma companies should prioritize criteria when selecting a CDMO for small molecule projects, including fit-for-purpose equipment, scale range, regulatory inspection history, nimbleness, and experience in target regulatory regions. Featuring panelist Natalie Farris, Executive CMC Consultant at Naltou Pharma CMC Consulting, LLC, and additional perspective from April Loui, SVP Quality and CMC Regulatory at ReCode Therapeutics, as well as Founder, CEO at Clarity Global Pharma.